Q3 Earnings Estimate for MDxHealth Issued By William Blair

MDxHealth SA (NASDAQ:MDXH) – Equities research analysts at William Blair dropped their Q3 2025 EPS estimates for shares of MDxHealth in a report issued on Thursday, May 15th. William Blair analyst A. Brackmann now forecasts that the company will post earnings per share of ($0.11) for the quarter, down from their prior forecast of ($0.09). The consensus estimate for MDxHealth’s current full-year earnings is ($1.15) per share. William Blair also issued estimates for MDxHealth’s Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.33) EPS.

MDxHealth (NASDAQ:MDXH) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The company had revenue of $24.29 million during the quarter, compared to the consensus estimate of $22.62 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%.

MDxHealth Stock Down 1.0%

MDxHealth stock opened at $2.07 on Monday. The company’s 50-day moving average price is $1.63 and its two-hundred day moving average price is $1.85. MDxHealth has a twelve month low of $1.35 and a twelve month high of $3.50. The stock has a market cap of $97.89 million, a P/E ratio of -1.36 and a beta of 1.32. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC acquired a new position in shares of MDxHealth during the 4th quarter worth approximately $25,000. Oppenheimer & Co. Inc. lifted its stake in MDxHealth by 100.0% in the 4th quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company’s stock valued at $47,000 after purchasing an additional 10,000 shares during the last quarter. Castleview Partners LLC bought a new position in MDxHealth in the 1st quarter valued at approximately $48,000. FAS Wealth Partners Inc. raised its stake in shares of MDxHealth by 49.6% during the fourth quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company’s stock valued at $58,000 after acquiring an additional 8,100 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of MDxHealth during the fourth quarter valued at $63,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.